Matt Kemp

🎗️In recognition of #ProstateCancerAwarenessMonth Urology Nevada is offering FREE PSA (Prostate-Specific Antigen) tests! This quick and easy blood test can detect early signs of prostate cancer, helping you stay ahead of your health. Early detection can lead to better treatment options and improved outcomes. Spots are limited and fill up fast, so call us this September to claim your appointment. Remember to schedule your test before the year ends. Early detection is key, so don’t miss out on this vital health check! 💙 . . . . . #ProstateHealth #FreePSATests #UrologyNevada #MensHealth

5

Recently, Dr. Alexandra MacLean, CEO of Avenue Therapeutics, hosted Dr. Christopher Grunseich (National Institute of Neurological Disorders and Stroke) and Dr. Tahseen Mozaffar (UC Irvine) in a virtual key opinion leader event to discuss #SpinalBulbarMuscularAtrophy (#SBMA), also known as #KennedysDisease. Currently, there are no FDA approved treatments for this rare neurodegenerative disease. The event focused on the current understanding of the condition including unmet needs, and an overview of Avenue’s Phase 1/2a trial of #AJ201 for the treatment of #KennedysDisease. Click here to view a replay of the event: https://lnkd.in/e5ZiDaiW

15

🚨 Breaking: InterVene, Inc. Secures $13M Series A Funding to Revolutionize Deep Vein Treatment 💥 InterVene, a Redwood City-based medtech leader, is pushing boundaries in chronic venous disease treatment. Here’s how they’re advancing vascular health with the recent Series A round: What’s Driving This Innovation: • Lead by Treo Ventures & RiverVest Venture Partners: Funding secured for final Recana catheter system development, clinical trials, and U.S. regulatory submission. 💰 • New Leadership Addition: Treo Ventures' Brad Vale joins InterVene’s Board, bringing deep expertise in medtech scaling. Why Recana is a Game-Changer: • Precision in Deep Vein Treatment: Recana is designed for recanalization in chronic deep vein obstructions, especially where conventional solutions fall short. • Seamless for Specialists: Uses Fluoroscopy/IVUS-guided techniques, aligning with methods already familiar to vascular specialists. ⚙️ Built on a Strong Foundation: Developed with support from the Stanford Biodesign Fellowship and residency at the Fogarty Institute, InterVene’s team of interventional experts is set to lead in deep venous care. The path to initial commercialization and post-market research is set, positioning InterVene as a significant player in venous disease innovation. 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs ♻️ Repost if you think this insight is worth sharing!

1

#PRIMR produces doctor-approved videos for trustworthy trial content. The RadiCaL Study is enrolling kidney cancer patients with bone metastases to explore if adding Ra-223 to cabozantinib improves patient outcomes. PI: Rana McKay UC San Diego Alliance for Clinical Trials in Oncology See IRB-approved video below 👇 https://lnkd.in/d97fj9dj #kidneycancer #kidneycancerawareness #cabozantinib #radium223 #radiopharmaceuticals #clinicaltrials #cancer #clinicalresearch #DEI #digital #health #immunotherapy #kidneycancer #men #menshealth #metastatickidneycancer #oncology #patienteducation #video #women #womenshealth #digital

1

Oragenics, Inc Partners with Avance Clinical for Phase II Concussion Trial in Australia SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a partnership with Avance Clinical, a leading Contract Research Organization (CRO), to conduct a Phase II clinical trial in Australia. This trial aims to evaluate Oragenics' lead drug candidate, ONP-002, for mild Traumatic Brain Injury (TBI), commonly known as concussion. ONP-002, a novel chemical entity (NCE), is delivered through a unique intranasal device and designed to maximize drug delivery directly to the brain. Avance Clinical, renowned for its clinical trial management capabilities and quality of service in Australia, New Zealand, and North America, brings over two decades of expertise in navigating the Therapeutic Goods Administration, Food and Drug Administration, and European Medicines Agency regulatory landscapes. An Oragenics Phase I clinical trial, recently completed in Australia under the management of Avance Clinical, demonstrated that ONP-002 is safe and well-tolerated. "Concussion remains a significant unmet medical need," said Dr. Jorgen Mould, Senior Director of Scientific and Regulatory Services at Avance Clinical. "Oragenics is poised to address this challenge, and we are delighted to be part of the team, especially given Australia's high incidence of sports-related concussions." Read the full Press Release 👇 https://lnkd.in/geAB5kMV #AvanceClinical #CRO #Concussion #Biotech #DrugDevelopment #Oragenics #TraumaticBrainInjury #TBI #SportsInjuries #Australia #AustralianAdvantage #ClinicalTrials #ClinicalResearch

50

🌟 Clinical Tips from the 20th Annual California Cancer Consortium Conference 2024 🌟 Reflecting on key takeaways from this year's conference, where experts shared groundbreaking insights in cancer research and treatment: 🔬 Expansion Cohorts in Early Phase Clinical Trials: Valuable or Not? 📝 How to Submit a Clinical Letter of Intent (LOI) to NCI/CTEP 🫁 Advances in Limited and Extensive Stage Small Cell Lung Cancer 💡 New Biomarkers in Breast Cancer ⚡ Novel Targets in Hematologic Malignancies These sessions highlighted cutting-edge advancements and strategies shaping the future of oncology. Excited to see where these innovations will lead! #CaliforniaCancerConsortium #CancerResearch #ClinicalTrials #SmallCellLungCancer #BreastCancer #HematologicMalignancies #Oncology #ClinicalTips #MedicalInnovation #NCI #CancerCare Primo Lara Timothy Synold Jonathan Riess Paul Frankel Percy Ivy Tycel Phillips

7

SFBN Feed: BridgeBio gathers investors to launch rare disease-focused spinoff https://lnkd.in/gQEigHGr The company earlier this year spun out a cancer-focused company with $200 million. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

3

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2

A new #CRISPR-based clinical trial for #SickleCell disease is enrolling at UCSF. This is the first therapy in the U.S. to apply non-viral CRISPR gene editing to directly correct the genetic mutation that causes the disease. Read more: https://ow.ly/Smry50UfZi1

32

🌟 Meet Dr. Hans Bock, MD: Chairman of Celero Global's Exclusive Advisory Board 🎊 We are delighted to welcome Dr. Hans Bock as the Chairman and Strategy Advisor of our esteemed and exclusive Advisory Board. With a distinguished career spanning over four decades in clinical research and development, Dr. Bock brings unparalleled expertise to his role. We are excited to have Dr. Bock at the helm of our exclusive Advisory Board, steering us with his visionary leadership and profound insights into the future of clinical research. #AdvisoryBoard #MeetTheTeam #ClinicalResearch #Biopharma #Biotech #CRO #PharmaInnovation #HealthcareLeadership #MedicalScience #DrugDevelopment #ClinicalTrials #LifeSciences #Biotechnology #PharmaIndustry #ResearchAndDevelopment #FutureOfHealthcare #PharmaCareers #Biomedical #Pharmaceuticals #ClinicalOperations #InnovativeMedicine #HealthTech #ScienceAndResearch #MedicalTechnology #BiopharmaNews #ClinicalTrialManagement #BiotechStartup #PharmaceuticalInnovation #MedicalResearch #HealthcareSolutions

13